New antiplatelet agent increases heart attack survival rate while reducing recurrence rate.
A new antiplatelet agent reduces the mortality and recurrence risks associated with heart attacks without increasing the risk of major bleeding. This has been shown by a large-scale international clinical study (PLATO) led by the Uppsala Clinical Research Center (UCR) at Uppsala University and Uppsala University Hospital and the Duke Clinical Research Institute in Durham, North Carolina, USA.